Objective To observe changes of plain MR T1WI signal intensity of dentate nucleus in nasopharyngeal carcinoma patients after radiotherapy and multiple times of intravenous injection of gadolinium-based contrast agent(...Objective To observe changes of plain MR T1WI signal intensity of dentate nucleus in nasopharyngeal carcinoma patients after radiotherapy and multiple times of intravenous injection of gadolinium-based contrast agent(GBCA).Methods Fifty patients with pathologically confirmed nasopharyngeal carcinoma and received intensity-modulated radiotherapy were retrospectively enrolled as the nasopharyngeal carcinoma group,and 50 patients with other malignant tumors and without history of brain radiotherapy were retrospectively enrolled as the control group.All patients received yearly GBCA enhanced MR examinations for the nasopharynx or the head.T1WI signal intensities of the dentate nucleus and the pons on same plane were measured based on images in the year of confirmed diagnosis(recorded as the first year)and in the second to the fifth years.T1WI signal intensity ratio of year i(ranging from 1 to 5)was calculated with values of dentate nucleus divided by values of the pons(ΔSI i),while the percentage of relative changes of year j(ranging from 2 to 5)was calculated withΔSI j compared toΔSI 1(Rchange j).The values of these two parameters were compared,and the correlation ofΔSI and GBCA injection year-time was evaluated within each group.Results No significant difference of gender,age norΔSI 1 was found between groups(all P>0.05).The second to the fifth yearΔSI and Rchange in nasopharyngeal carcinoma group were all higher than those in control group(all P<0.05).Within both groups,ΔSI was positively correlated with GBCA injection year-time(both P<0.05).Conclusion Patients with nasopharyngeal carcinoma who underwent radiotherapy and multiple times of intravenous injection of GBCA tended to be found with gradually worsening GBCA deposition in dentate nucleus,for which radiotherapy might be a risk factor.展开更多
目的 分析食管癌患者接受放疗/放化疗后营养状态恶化的影响因素,为抗肿瘤治疗期间的营养管理提供参考。方法 选取2017年12月至2023年12月在安徽医科大学附属安庆第一人民医院接受放疗或放化疗的食管癌患者106例,收集患者性别、年龄、手...目的 分析食管癌患者接受放疗/放化疗后营养状态恶化的影响因素,为抗肿瘤治疗期间的营养管理提供参考。方法 选取2017年12月至2023年12月在安徽医科大学附属安庆第一人民医院接受放疗或放化疗的食管癌患者106例,收集患者性别、年龄、手术史、放疗干预时机、是否同步放化疗、放疗剂量、临床分期、初始营养状态、行为状况评分等资料,监测抗肿瘤治疗前后患者主观整体营养评估量表评分变化。根据入组开始和放疗结束时营养状态将患者分为营养状态恶化组与非恶化(稳定或改善)组,比较两组患者临床特征的差异,通过logistic回归分析筛选营养状态恶化的影响因素,通过Spearman相关分析探讨营养状态恶化与不良反应(放射性食管炎、肺部感染、中性粒细胞减少、血小板减少、转氨酶升高)的相关性。结果 食管癌放疗/放化疗后营养状态恶化组与非恶化组患者性别、放疗剂量、初始营养状态、行为状况评分差异均无统计学意义(均P>0.05),营养状态恶化组既往食管癌手术史、同步放化疗、低于90%目标能量需求量时启动放疗、临床分期为Ⅳ期的患者比例均高于非恶化组(均P<0.05)。logistic回归分析显示,临床分期为Ⅳ期(OR=4.684,95% CI 1.252~17.519,P=0.022)、既往食管癌手术史(OR=7.338,95% CI 1.878~28.666,P=0.004)是食管癌患者放疗/放化疗后营养状态恶化的独立不良风险因素;放疗干预时机也是食管癌患者放疗/放化疗后营养状态恶化的独立影响因素,以耐受70%~90%目标能量需求量为参照水平,在耐受90%~100%目标能量需求量时启动放疗具有最优的营养状态保护作用(OR=0.166,95% CI 0.050~0.551,P=0.003)。Spearman相关分析显示营养状态恶化与放疗后转氨酶升高呈正相关(r_s=0.283,P=0.003),与其他不良反应无相关性(均P>0.05)。结论 标准营养干预模式下,既往手术和复发转移食管癌患者接受放疗/放化疗仍存在营养状态恶化风险,耐受90%~100%目标能量需求量可能是放疗干预较为合适的时机,治疗期间营养状态恶化时需警惕转氨酶升高。展开更多
Background and objective Recent studies have showed that combination of chemotherapy and radiotherapy might result in better outcome for locally advanced non-small cell lung cancer (NSCLC). The aim of this study is to...Background and objective Recent studies have showed that combination of chemotherapy and radiotherapy might result in better outcome for locally advanced non-small cell lung cancer (NSCLC). The aim of this study is to determine the maximal tolerance dose (MTD) and efficacy of full-dose gemcitabine and oxaliplatin when given concurrently with 3-dimentional radiation therapy (3D-RT) for locally advanced NSCLC. Methods Oxaliplatin was administered at a fixed dose of 130mg/m^2, and gemcitabine was administered at a starting dose of 800mg/m^2 with an incremental dose gradient of 200mg/m^2 for 3 dose levels. MTD was defined as the immediate dose level lower than the dose at which dose-limiting toxicity (DLT) occurred in more than one-third of the patients. The chemotherapy was administered at 3-week cycle. The RT was given as 3-D conformal manner at a single daily dose of 2Gy for 5 days per week. Results Twenty-two patients were evaluable and distributed to three different dose levels: 6 at level 1, 8 at level 2 and 8 at level 3. Pulmonary toxicity, esophageal and hematologic toxicity were the main DLT. Grade Ⅲ acute pulmonary toxicity occurred in one patient each at level 2 and level 3, both with V20>20%, and grade Ⅲ esophagitis in two patients at level 3. The MTD of gemcitabine in this study was 1000mg/m^2. The overall response rate was 75.0% (9/12). The 1- and 2-year survival rate was 70.0% and 30.5% respectively. The median time to progression was 8.7 months (range 5--11.8 months). Conclusion With reduced radiation volume, gemcitabine of 1000mg/m^2 in combination with oxaliplatin of 130mg/m^2 was effective and could be safely administered for NSCLC.展开更多
Breathlessness, fatigue, and anxiety are distressing symptoms for patients with advanced lung cancer, however, they are not relieved by palliative RT and are often viewed as neglected areas of clinical practice. This ...Breathlessness, fatigue, and anxiety are distressing symptoms for patients with advanced lung cancer, however, they are not relieved by palliative RT and are often viewed as neglected areas of clinical practice. This paper aims to review def initions of, and explore patients' experiences of, breathlessness, fatigue, and anxiety. Further, it will outline existing approaches, both pharmacological and non-pharmacological, to treat them. Current treatments and perceptions of these symptoms will be discussed in the context of Hong Kong health care service. The review of literature also shows that breathlessness, fatigue and anxiety appears to have similar emotional origins. A contemporary approach of using a common pyschoeducational intervention to treat these symptoms together as a cluster in end of life care will be discussed.展开更多
文摘Objective To observe changes of plain MR T1WI signal intensity of dentate nucleus in nasopharyngeal carcinoma patients after radiotherapy and multiple times of intravenous injection of gadolinium-based contrast agent(GBCA).Methods Fifty patients with pathologically confirmed nasopharyngeal carcinoma and received intensity-modulated radiotherapy were retrospectively enrolled as the nasopharyngeal carcinoma group,and 50 patients with other malignant tumors and without history of brain radiotherapy were retrospectively enrolled as the control group.All patients received yearly GBCA enhanced MR examinations for the nasopharynx or the head.T1WI signal intensities of the dentate nucleus and the pons on same plane were measured based on images in the year of confirmed diagnosis(recorded as the first year)and in the second to the fifth years.T1WI signal intensity ratio of year i(ranging from 1 to 5)was calculated with values of dentate nucleus divided by values of the pons(ΔSI i),while the percentage of relative changes of year j(ranging from 2 to 5)was calculated withΔSI j compared toΔSI 1(Rchange j).The values of these two parameters were compared,and the correlation ofΔSI and GBCA injection year-time was evaluated within each group.Results No significant difference of gender,age norΔSI 1 was found between groups(all P>0.05).The second to the fifth yearΔSI and Rchange in nasopharyngeal carcinoma group were all higher than those in control group(all P<0.05).Within both groups,ΔSI was positively correlated with GBCA injection year-time(both P<0.05).Conclusion Patients with nasopharyngeal carcinoma who underwent radiotherapy and multiple times of intravenous injection of GBCA tended to be found with gradually worsening GBCA deposition in dentate nucleus,for which radiotherapy might be a risk factor.
文摘目的 分析食管癌患者接受放疗/放化疗后营养状态恶化的影响因素,为抗肿瘤治疗期间的营养管理提供参考。方法 选取2017年12月至2023年12月在安徽医科大学附属安庆第一人民医院接受放疗或放化疗的食管癌患者106例,收集患者性别、年龄、手术史、放疗干预时机、是否同步放化疗、放疗剂量、临床分期、初始营养状态、行为状况评分等资料,监测抗肿瘤治疗前后患者主观整体营养评估量表评分变化。根据入组开始和放疗结束时营养状态将患者分为营养状态恶化组与非恶化(稳定或改善)组,比较两组患者临床特征的差异,通过logistic回归分析筛选营养状态恶化的影响因素,通过Spearman相关分析探讨营养状态恶化与不良反应(放射性食管炎、肺部感染、中性粒细胞减少、血小板减少、转氨酶升高)的相关性。结果 食管癌放疗/放化疗后营养状态恶化组与非恶化组患者性别、放疗剂量、初始营养状态、行为状况评分差异均无统计学意义(均P>0.05),营养状态恶化组既往食管癌手术史、同步放化疗、低于90%目标能量需求量时启动放疗、临床分期为Ⅳ期的患者比例均高于非恶化组(均P<0.05)。logistic回归分析显示,临床分期为Ⅳ期(OR=4.684,95% CI 1.252~17.519,P=0.022)、既往食管癌手术史(OR=7.338,95% CI 1.878~28.666,P=0.004)是食管癌患者放疗/放化疗后营养状态恶化的独立不良风险因素;放疗干预时机也是食管癌患者放疗/放化疗后营养状态恶化的独立影响因素,以耐受70%~90%目标能量需求量为参照水平,在耐受90%~100%目标能量需求量时启动放疗具有最优的营养状态保护作用(OR=0.166,95% CI 0.050~0.551,P=0.003)。Spearman相关分析显示营养状态恶化与放疗后转氨酶升高呈正相关(r_s=0.283,P=0.003),与其他不良反应无相关性(均P>0.05)。结论 标准营养干预模式下,既往手术和复发转移食管癌患者接受放疗/放化疗仍存在营养状态恶化风险,耐受90%~100%目标能量需求量可能是放疗干预较为合适的时机,治疗期间营养状态恶化时需警惕转氨酶升高。
文摘Background and objective Recent studies have showed that combination of chemotherapy and radiotherapy might result in better outcome for locally advanced non-small cell lung cancer (NSCLC). The aim of this study is to determine the maximal tolerance dose (MTD) and efficacy of full-dose gemcitabine and oxaliplatin when given concurrently with 3-dimentional radiation therapy (3D-RT) for locally advanced NSCLC. Methods Oxaliplatin was administered at a fixed dose of 130mg/m^2, and gemcitabine was administered at a starting dose of 800mg/m^2 with an incremental dose gradient of 200mg/m^2 for 3 dose levels. MTD was defined as the immediate dose level lower than the dose at which dose-limiting toxicity (DLT) occurred in more than one-third of the patients. The chemotherapy was administered at 3-week cycle. The RT was given as 3-D conformal manner at a single daily dose of 2Gy for 5 days per week. Results Twenty-two patients were evaluable and distributed to three different dose levels: 6 at level 1, 8 at level 2 and 8 at level 3. Pulmonary toxicity, esophageal and hematologic toxicity were the main DLT. Grade Ⅲ acute pulmonary toxicity occurred in one patient each at level 2 and level 3, both with V20>20%, and grade Ⅲ esophagitis in two patients at level 3. The MTD of gemcitabine in this study was 1000mg/m^2. The overall response rate was 75.0% (9/12). The 1- and 2-year survival rate was 70.0% and 30.5% respectively. The median time to progression was 8.7 months (range 5--11.8 months). Conclusion With reduced radiation volume, gemcitabine of 1000mg/m^2 in combination with oxaliplatin of 130mg/m^2 was effective and could be safely administered for NSCLC.
文摘Breathlessness, fatigue, and anxiety are distressing symptoms for patients with advanced lung cancer, however, they are not relieved by palliative RT and are often viewed as neglected areas of clinical practice. This paper aims to review def initions of, and explore patients' experiences of, breathlessness, fatigue, and anxiety. Further, it will outline existing approaches, both pharmacological and non-pharmacological, to treat them. Current treatments and perceptions of these symptoms will be discussed in the context of Hong Kong health care service. The review of literature also shows that breathlessness, fatigue and anxiety appears to have similar emotional origins. A contemporary approach of using a common pyschoeducational intervention to treat these symptoms together as a cluster in end of life care will be discussed.
